KIT and congenital bilateral aplasia of vas deferens from CFTR mutation: These findings pinpoint a previously unidentified regulatory DHM/c-KIT/IL-6 axis contributing to CAVD, suggesting that DHM might be an effective chemical drug for the treatment of CAVD.